John D. Shire

Co-Chair, Health Care & Life Sciences

John focuses his corporate and transactional practice on the health care and life sciences industry and other highly regulated activities. He represents public and private companies in acquisitions, investments, debt financings, joint ventures, commercial contracts, private placements, and impact investments. He also represents private funds in formation, structural matters, and capital allocation within the health care life sciences space and digital medicine space.

With a deep understanding of federal and state health care regulations governing reimbursement, fraud and abuse, compliance and enforcement matters, John has led several of the most recognized transactions in the U.S. health care arena. John routinely advises health care operators and private equity firms in health care transactional, regulatory, and licensing matters. Specifically, John advises health care systems, hospitals, specialty-care providers, GPOs, and specialty-pharma suppliers in transactions and compliance with Medicare, Medicaid, and U.S. Department of Justice initiatives, such as CID responses.

In addition to transactional and regulatory counseling for the health care industry, John serves as outside general counsel to a variety of entities at the leading edge of innovation. He has unique experience representing investment banks and private funds in technology and digital health care transactions and equity trading in transactions involving nuclear fuel, enriched fuel, and PPA agreements.



Cozen O’Connor Makes Strategic Move Adding John D. Shire to Washington, D.C. Health Care Practice

November 02, 2020

Shire brings a deep understanding of federal and state health care regulations and has been instrumental in several of the most well-known transactions in the health care space.


Industry Interactions with Physicians Continue to be a Hot Topic for Civil False Claims Act Enforcement Actions under Private Qui Tam Litigation [Health Law Informer Blog]

October 06, 2022

In a continuing wave of fraud and abuse civil enforcement actions brought by qui tam relators, big pharma giant, Biogen, is the latest corporate actor to reach a mega settlement with the U.S. Department of Justice (DOJ) for allegations of False Claims Act liability for paying bribes to physicians...


  • Dickinson School of Law, J.D.
  • Bucknell University, B.A.
  • District of Columbia
  • Maryland
  • New Jersey
  • Pennsylvania

Board of Directors, Florida Venture Forum